EU: Patient registries may prove valuable in regulatory decisions, EMA study finds


EU: Patient registries may prove valuable in regulatory decisions, EMA study finds

(Source: RAPS 2019-07-23)

Although patient registries can be heterogenous in their quality and design, a new study in Drug Safety co-authored by a European Medicines Agency (EMA) official explains how patient registries could provide valuable data for regulatory decisions.

The authors explain how such registries can be used when randomized controlled trials are not feasible, such as with some rare diseases, or to meet postmarketing commitments.

“For products granted conditional marketing approval, registry studies may provide post-authorisation data to fulfil regulator-imposed specific obligations to confirm safety and/or effectiveness, as is the case with the recently authorised chimeric antigen receptor (CAR) T-cell products, tiagenlecleucel and axicabtagene ciloleucel,” the study says.

The eight authors, from EMA, Queens Mary University of London, the University of Groningen in the Netherlands and the Dutch Medicines Evaluation Board, also explain how registries are currently underused.

Of 335 products recommended for approval by EMA’s Committee for Medicinal Products for Human Use between 2005 and 2013, 31 registries were requested to fulfill a condition of the marketing authorization, but by December 2017, just ten had been completed.

To try to figure out what factors facilitate registry use, the authors synthesized observations and recommendations published in five reports arising from a multi-stakeholder EMA consultation and four disease-specific workshops conducted as part of EMA’s Patient Registries Initiative.

To continue reading this article please go to RAPS

EMA Study

New Article